{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=29", "query": { "condition": "Phase II", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 21412, "total_pages": 2142, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T17:56:46.245Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02119468", "title": "Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Plasma Cell Myeloma", "Recurrent Plasma Cell Myeloma" ], "interventions": [ { "name": "ixazomib citrate", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2014-07-22", "completion_date": "2022-12-01", "has_results": true, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-15T17:56:46.245Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Duarte, California • Atlanta, Georgia + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02119468" }, { "nct_id": "NCT05419050", "title": "Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fibrous Dysplasia" ], "interventions": [ { "name": "denosumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Dental and Craniofacial Research (NIDCR)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "14 Years", "sex": "ALL", "summary": "4 Years to 14 Years" }, "enrollment_count": 15, "start_date": "2022-10-12", "completion_date": "2026-01-09", "has_results": false, "last_update_posted_date": "2026-01-20", "last_synced_at": "2026-11-15T17:56:46.245Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05419050" }, { "nct_id": "NCT01643850", "title": "MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pigmented Villonodular Synovitis", "PVNS", "Giant Cell Tumor of the Tendon Sheath", "GCCTS", "Tenosynovial Giant Cell Tumor Localized or Diffused Type", "GCTS" ], "interventions": [ { "name": "MCS110", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 36, "start_date": "2012-04-23", "completion_date": "2018-12-21", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-11-15T17:56:46.245Z", "location_count": 7, "location_summary": "San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01643850" }, { "nct_id": "NCT00532259", "title": "CT-011 MAb in DLBCL Patients Following ASCT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Large Cell, Diffuse", "Lymphoma, Mixed Cell, Diffuse", "Primary Mediastinal Large B-Cell Lymphoma" ], "interventions": [ { "name": "CT-011", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CureTech Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2007-10", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2014-09-12", "last_synced_at": "2026-11-15T17:56:46.245Z", "location_count": 20, "location_summary": "La Jolla, California • San Diego, California • Atlanta, Georgia + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00532259" }, { "nct_id": "NCT00374296", "title": "MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelogenous Leukemia, Acute", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "MGCD0103", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2006-09", "completion_date": "2008-09", "has_results": false, "last_update_posted_date": "2015-07-01", "last_synced_at": "2026-11-15T17:56:46.245Z", "location_count": 6, "location_summary": "Kansas City, Missouri • Rochester, New York • Canton, Ohio + 3 more", "locations": [ { "city": "Kansas City", "state": "Missouri" }, { "city": "Rochester", "state": "New York" }, { "city": "Canton", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00374296" }, { "nct_id": "NCT00666588", "title": "Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Childhood Acute Basophilic Leukemia", "Childhood Acute Eosinophilic Leukemia", "Childhood Acute Erythroleukemia (M6)", "Childhood Acute Megakaryocytic Leukemia (M7)", "Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)", "Childhood Acute Monoblastic Leukemia (M5a)", "Childhood Acute Monocytic Leukemia (M5b)", "Childhood Acute Myeloblastic Leukemia With Maturation (M2)", "Childhood Acute Myeloblastic Leukemia Without Maturation (M1)", "Childhood Acute Myelomonocytic Leukemia (M4)", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "idarubicin", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 52, "start_date": "2008-04", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2018-05-22", "last_synced_at": "2026-11-15T17:56:46.245Z", "location_count": 77, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 72 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00666588" }, { "nct_id": "NCT00004161", "title": "Fenretinide in Treating Patients With Leukoplakia of the Mouth", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "fenretinide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "1997-06", "completion_date": "2004-01", "has_results": false, "last_update_posted_date": "2013-04-12", "last_synced_at": "2026-11-15T17:56:46.245Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004161" }, { "nct_id": "NCT00313586", "title": "Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1", "Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL", "Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA", "Alkylating Agent-Related Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "de Novo Myelodysplastic Syndrome", "Previously Treated Myelodysplastic Syndrome", "Recurrent Adult Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndrome", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Entinostat", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 197, "start_date": "2006-08", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2017-02-02", "last_synced_at": "2026-11-15T17:56:46.245Z", "location_count": 234, "location_summary": "Scottsdale, Arizona • Burbank, California • Los Angeles, California + 146 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Roseville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00313586" }, { "nct_id": "NCT06215586", "title": "Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Failure", "Heart Failure Preserved Ejection Fraction", "Cardiovascular Diseases", "Heart Diseases" ], "interventions": [ { "name": "Tovinontrine (CRD-750)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cardurion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 303, "start_date": "2024-02-13", "completion_date": "2025-09-02", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-11-15T17:56:46.245Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Orange", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Van Nuys", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06215586" }, { "nct_id": "NCT04844970", "title": "Anamorelin Study for Advanced Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Anamorelin Hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lahey Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2023-04-01", "completion_date": "2023-11-07", "has_results": true, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-11-15T17:56:46.245Z", "location_count": 1, "location_summary": "Burlington, Massachusetts", "locations": [ { "city": "Burlington", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04844970" } ] }